Menu Search
Equities

Shockwave Medical Inc

SWAV*:MEX

Shockwave Medical Inc

Actions
  • Price (MXN)5,518.32
  • Today's Change-3.84 / -0.07%
  • Shares traded-1.00
  • 1 Year change+12.50%
  • Beta--
Data delayed at least 20 minutes, as of Aug 28 2023 12:30 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Shockwave Medical, Inc. is a medical device company. The Company is primarily engaged in the development and commercialization of novel technologies that transform the care of patients with cardiovascular disease. The Company is focused on its intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular and heart valve disease. Built on a balloon catheter platform, the IVL technology uses lithotripsy to disrupt both superficial and deep vascular calcium., while minimizing soft tissue injury, and an integrated angioplasty balloon to dilate blockages at low pressures, restoring blood flow. Its Shockwave M5 IVL catheter and Shockwave M5+ IVL catheter are five-emitter catheters for use in its IVL System in medium-diameter vessels for the treatment of peripheral artery disease (PAD). Its Shockwave S4 IVL catheter is a four-emitter catheter for use in its IVL System in small-diameter vessels for the treatment of PAD.

  • Revenue in USD (TTM)787.97m
  • Net income in USD163.50m
  • Incorporated2009
  • Employees1.47k
  • Location
    Shockwave Medical Inc5403 Betsy Ross DrSANTA CLARA 95054United StatesUSA
  • Phone+1 (510) 279-4262
  • Fax+1 (302) 636-5454
  • Websitehttps://shockwavemedical.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.